期刊
INVESTIGATIONAL NEW DRUGS
卷 28, 期 3, 页码 234-241出版社
SPRINGER
DOI: 10.1007/s10637-009-9232-x
关键词
Makaluvamine; Prostate cancer; Chemotherapy; Cell cycle; Apoptosis
资金
- NIH [R01 CA112029, R01 CA121211, P60 AR20614]
- DoD [W81XWH-06-1-0063]
- NIH/UAB [CA075930]
- UAB Council of University-Wide Interdisciplinary Research Centers
- NATIONAL CANCER INSTITUTE [T32CA075930, R01CA121211, R01CA112029] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER
We recently synthesized a series of novel makaluvamine compounds, and found that the most potent was FBA-TPQ. The effects of FBA-TPQ on human (LNCaP and PC3) and murine (TRAMP C1) prostate cancer cells were evaluated. Potential mechanisms of action of the compound were also determined. FBA-TPQ exhibited dose-dependent cytotoxicity in the low micromolar range, inhibited proliferation, caused cell cycle arrest, and induced apoptosis in prostate cancer cell lines. The compound also decreased the expression of the androgen receptor and PSA. The results presented herein support the further development of FBA-TPQ as a novel agent for prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据